A First-in-human, Dose Escalation, and Expansion Study of BNT3211 for Participants With Advanced Solid Tumors
A Phase I/II, First-in-human, Open-label, Multi-site, Dose Escalation and Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BNT3211 in Participants With Advanced Solid Tumors
This study is the first time BNT3211 will be tested in people. It will evaluate different dose levels of BNT3211 in adults to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.
調査の概要
詳細な説明
This study will consist of two parts (A and B). Part A will be a dose escalation to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BNT3211. Part B will be a dose optimization and proof-of-concept to further investigate the safety, tolerability and preliminarily antitumor activity of BNT3211 at doses selected from Part A. Part B will enroll participants with the same indications as in Part A.
No randomization will be performed in Part A. In Part B, for each selected indication, participants are randomized to the doses selected at the end of Part A using a dynamic allocation procedure.
There will be a screening period, a treatment period, and a follow-up period (including an end-of-treatment visit, a safety follow-up visit, and a survival follow-up period with regular visits).
Participants will receive BNT3211 until disease progression, start of new anticancer treatment, unacceptable toxicity, withdrawal of consent, or until the sponsor terminates the study or any other criterion for discontinuation is met.
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:BioNTech clinical trials patient information
- 電話番号:+49 6131 9084
- メール:patients@biontech.de
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
- Are ≥18 years of age (local laws will be followed if the age of consent is older).
- Have an Eastern Cooperative Oncology Group performance status of 0 to 1.
- Have a life expectancy of ≥3 months in the opinion of the investigator.
- Have at least one measurable lesion as per RECIST v1.1.
- Have an archival formalin-fixed paraffin-embedded tumor tissue sample available or are willing to be biopsied to obtain a fresh tumor tissue sample.
- Have histologically or cytologically confirmed locally advanced, recurrent, or metastatic solid tumors and must have received all available standard of care (SoC) treatment in accordance with local practice (unless the standard therapy is considered inappropriate or intolerable) and failed at least first-line SoC therapy prior to enrollment.
- Have an adequate coagulation, hematologic, and organ function as defined by the protocol.
- Left ventricular ejection fraction (LVEF) ≥50% by either echocardiogram or multi-gated acquisition scan within 28 days prior to first dose of study treatment.
Key Exclusion Criteria:
-
Have had major surgery (not including diagnostic surgery) within the 4 weeks prior to the first dose of study treatment or are planned to undergo major surgery during the course of the study.
-
Have had prior allogeneic bone marrow transplantation or solid-organ transplantation.
-
Have had an inadequate washout period for prior anticancer treatment or other restricted medications prior to the first dose of investigational medicinal product (IMP) as defined in the protocol.
-
Have received systemic steroids (>10 mg/day of prednisone or its equivalent) or other immunosuppressive therapy within 2 weeks prior to the first dose of IMP. Protocol defined exceptions apply.
-
Have received any live or attenuated vaccine within 4 weeks prior to the first dose of IMP or intend to receive a live or attenuated vaccine during the study.
-
Have a history of leptomeningeal carcinomatosis.
-
Have brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anticonvulsants for at least 2 weeks prior to the first dose of IMP.
-
Have a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that requires steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. Protocol-defined exceptions apply.
-
Have clinically significant concomitant pulmonary disease, including but not limited to: chronic obstructive pulmonary disease, restrictive lung disease, lung injury accompanied with autoimmune disease/connective tissue disorders.
-
Have uncontrolled pleural effusions, ascites, or pericardial effusions that require repeated drainage (once monthly or more frequently).
-
Have active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal conditions that may cause bleeding or perforation in the opinion of the treating investigator.
-
Have an active infection that requires systemic therapy (except for oral antibiotics) within 1 week prior to the first dose of IMP. Participants receiving prophylactic anti-infective therapy (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) may be eligible.
-
Have active or chronic corneal disorders, or other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease that prevents adequate monitoring of drug-induced keratopathy.
-
Have a known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Protocol defined exceptions apply.
-
Have any other primary malignancy within 3 years prior to the first dose of IMP, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other curatively treated solid tumors.
-
Have unresolved toxicities from previous anticancer therapy, defined as toxicities not yet resolved according to (US) National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Grade ≤1 (unless the investigator determines that certain AEs pose no safety risk to the participant, such as hair loss, Grade 2 peripheral neuropathy or stable hypothyroidism under hormone replacement therapy).
-
Have any of the following heart conditions within 6 months prior to the study treatment:
- Acute coronary syndrome, coronary artery bypass grafting, congestive heart failure, aortic dissection, stroke, or other Grade 3 and above cardiovascular and cerebrovascular events.
- New York Heart Association functional classification ≥II heart failure or LVEF <50%.
- Ventricular arrhythmias requiring clinical intervention, second- to third-degree atrioventricular block, or congenital long QT syndrome. Participants with treated cardiac arrhythmia/atrial fibrillation are allowed.
- Mean QT interval corrected by Fridericia's method >450 ms for males or >470 ms for females in three successive screening measurements based on a 12-lead electrocardiogram.
-
Unstable thrombotic event (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 3 months.
Note: Other protocol defined inclusion and exclusion criteria apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Part A (dose escalation) - BNT3211 monotherapy
Escalating dose levels of BNT3211. |
Intravenous infusion |
|
実験的:Part B (dose optimization) - BNT3211 monotherapy
Indications as in Part A. Doses will be selected from Part A. |
Intravenous infusion |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part A only - Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation period
時間枠:Up to 21 days from the initiation of first dose of BNT3211
|
DLT period defined as the first 21 days. Per dose level. |
Up to 21 days from the initiation of first dose of BNT3211
|
|
Number of participants with treatment emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs
時間枠:From first dose until 35 days after the last dose of BNT3211 (up to 36 months)
|
Per dose level (Part A) and per arm (Part B). |
From first dose until 35 days after the last dose of BNT3211 (up to 36 months)
|
|
Number of participants with dose interruptions, reductions, or discontinuations of study treatment due to TEAEs
時間枠:From the first until the last dose of BNT3211 (up to 36 months)
|
Per dose level (Part A) and per arm (Part B). |
From the first until the last dose of BNT3211 (up to 36 months)
|
|
Part B only - Objective response rate
時間枠:Up to 36 months
|
Defined as the proportion of participants with confirmed complete response (CR) or partial response (PR) (per the Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1] based on the investigator's assessment) is observed as best overall response. Per arm. |
Up to 36 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
PK assessment: Area under the curve (AUC) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
時間枠:Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
|
After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits. |
Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
|
|
PK assessment: Maximum concentration (Cmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
時間枠:Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
|
After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits. |
Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
|
|
PK assessment: Time to reach maximum (peak) serum concentration (Tmax) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
時間枠:Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
|
After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits. |
Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
|
|
PK assessment: Elimination half-life (t1/2) derived from serum concentrations of BNT3211, total antibody and unconjugated payload
時間枠:Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
|
After single- and multiple-dosing. Per dose level (Part A) and per arm (Part B). As data permits. |
Up to approximately 35 days after the last dose of BNT3211 (up to 36 months)
|
|
Part A only - Objective response rate
時間枠:Up to 36 months
|
Defined as the proportion of participants with confirmed CR or PR (per RECIST v1.1 based on the investigator's assessment) is observed as best overall response. Per dose level. |
Up to 36 months
|
|
Disease control rate
時間枠:Up to 36 months
|
Defined as the proportion of participants in whom a confirmed CR, confirmed PR or stable disease (SD) (per RECIST v1.1 based on the investigator's assessment, SD assessed at least 6 weeks [±7 days] after the first BNT3211 dose) is observed as best overall response. Per dose level (Part A) and per arm (Part B). |
Up to 36 months
|
|
Duration of response
時間枠:Up to 36 months
|
Defined as the time from first objective response (CR or PR per RECIST v1.1 based on the investigator's assessment) to first occurrence of objective tumor progression (progressive disease per RECIST v1.1 based on the investigator's assessment) or death from any cause, whichever occurs first. Per dose level (Part A) and per arm (Part B). |
Up to 36 months
|
|
Part B only - Progression free survival
時間枠:Up to 36 months
|
Defined as the time from first dose of BNT3211 to first objective tumor progression (PD per RECIST 1.1 based on the investigator's assessment), or death from any cause, whichever occurs first. Per arm. |
Up to 36 months
|
|
Part B only - Overall survival
時間枠:Up to 36 months
|
Defined as the time from first dose of BNT3211 to death from any cause. Per arm. |
Up to 36 months
|
|
Anti-drug antibody prevalence
時間枠:For up to 35 days from the last dose of BNT3211 (up to 36 months)
|
Defined as proportion of participants who are anti-drug antibody positive (either baseline or post-baseline). Per dose level (Part A) and per arm (Part B). As data permits. |
For up to 35 days from the last dose of BNT3211 (up to 36 months)
|
|
Anti-drug antibody incidence
時間枠:For up to approximately 35 days from the last dose of BNT3211 (up to 36 months)
|
Defined as proportion of participants having treatment-emergent anti-drug antibodies. Per dose level (Part A) and per arm (Part B). As data permits. |
For up to approximately 35 days from the last dose of BNT3211 (up to 36 months)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:BioNTech Responsible Person、BioNTech SE
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- BNT3211-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。